A Systematic Review of a Single-Class Maintenance Strategy with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Hiv/Aids

Thompson M.A. , Aberg J.A. , Hoy J.F. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387–402.

Friis-Møller N. , Sabin C.A. , Weber R. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993–2003.

Friis-Møller N. , Reiss P. , Sabin C.A. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723–1735.

Sabin C.A. , Worm S.W. , Weber R. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417–1426.

Cruciani M. , Zanichelli V. , Serpelloni G. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993–2004.

Ding X. , Andraca-Carrera E. , Cooper C. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61: 441–447.

Staszewski S. , Keiser P. , Montaner J. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285: 1155–1163.

Vibhagool A. , Cahn P. , Schechter M. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004; 20: 1103–1114.

Matheron S. , Descamps D. , Boue F. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8: 163–171.

Kumar P.N. , Rodriguez-French A. , Thompson M.A. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006; 7: 85–98.

Kumar P.N. , Salvato P. , Lamarca A. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther 2009; 6: 3.

Shapiro R.L. , Hughes M.D. , Ogwu A. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282–2294.

Gulick R.M. , Ribaudo H.J. , Shikuma C.M. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850–1861.

Bartlett J.A. , Johnson J. , Herrera G. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006; 43: 284–292.

Mugyenyi P. , Walker A.S. , Hakim J. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123–131.

DART trial team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/ lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13: 6–16.

Munderi P. , Walker A.S. , Kityo C. Nevirapine/ zidovudine/lamivudine has superior immunological and virological responses not refected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/ lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 2010; 11: 334–344.

Ndembi N. , Goodall R.L. , Dunn D.T. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis 2010; 201: 106–113.

Walker A.S. , Munderi P. , Kityo C. Long-term randomised comparison of clinical outcomes following ART institution with triple-nuecleoside (combivir/abacavir) or NNRTI-based (combivir/nevirapine) therapy in Africa: the NORA substudy of the DART trial. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract MOPEB057.

van Leeuwen R. , Katlama C. , Murphy R.L. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987–999.

Gerstoft J. , Kirk O. , Obel N. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17: 2045–2052.

Landman R. , Descamps D. , Peytavin G. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6: 291–301.

Gallant J.E. , Rodriguez A.E. , Weinberg W.G. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921–1930.

Khanlou H. , Yeh V. , Guyer B. , Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19: 135–140.

Kirkland L.R. , Fischl M.A. , Tashima K.T. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002; 34: 511–518.

DART trial group. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391–1399.

Rey D. , Krebs M. , Partisani M. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2006; 43: 530–534.

Masquelier B. , Neau D. , Boucher S. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/ tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Antivir Ther 2006; 11: 827–830.

Elion R. , Cohen C. , DeJesus E. Once-daily abacavir/ lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: a 48-week pilot study. HIV Clin Trials 2006; 7: 324–333.

Moyle G. , Higgs C. , Teague A. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 2006; 11: 73–78.

Ferrer E. , Gatell J.M. , Sanchez P. Zidovudine/ lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. AIDS Res Hum Retroviruses 2008; 24: 931–934.

Puls R.L. , Srasuebkul P. , Petoumenos K. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51: 855–864.

Shey M.S. , Kongnyuy E.J. , Alobwede S.M. , Wiysonge C.S. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database Syst Rev 2013; 3: CD005481.

Pialoux G. , Raff F. , Brun-Vezinet F. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998; 339: 1269–1276.

Havlir D.V. , Marschner I.C. , Hirsch M.S. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339: 1261–1268.

Bierman W.F. , van Agtmael M.A. , Nijhuis M. , Danner S.A. , Boucher C.A. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23: 279–291.

McKinnon J.E. , Mellors J.W. , Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009; 14: 1–12.

Mathis S. , Khanlari B. , Pulido F. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE 2011; 6: e22003.

Calza L. , Manfredi R. Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. Curr HIV Res 2012; 10: 661–672.

Bucher H.C. , Kofler A. , Nuesch R. , Young J. , Battegay M. , Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17: 2451–2459.

Kessler H.A. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. MedGenMed 2005; 7: 70.

Rizzardini G. , Capetti A. Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review. Med Sci Monit 2006; 12: RA269–RA276.

Cruciani M. , Mengoli C. , Serpelloni G. , Parisi S.G. , Malena M. , Bosco O. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database Syst Rev 2013; 6: CD008270.

Jadad A.R. , Moore R.A. , Carroll D. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.

The Ottowa Hospital Research Institute. The Newcastle-Ottowa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Accessed 1 March 2013.) Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Moyle G.J. , Gazzard B.G. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002; 16: 1086–1087.

John M. , McKinnon E.J. , James I.R. Randomized, controlled, 48-week study of switching stavudine and/ or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29–33.

Moyle G.J. , Baldwin C. , Langroudi B. , Mandalia S. , Gazzard B.G. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22–28.

Hoogewerf M. , Regez R.M. , Schouten W.E. , Weigel H.M. , Frissen P.H. , Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362: 1979–1980.

van Raalte R. , Heere B. , Regez R. Induction-maintenance strategy re-evaluated: initial boosted-PI in combination with triple NRTI, followed by triple NRTI maintenance. 15th International Conference on AIDS. 11–14 July 2004, Bangkok, Thailand. Abstract TuPeB4597.

d'Ettorre G. , Mastroianni C.M. , Massetti A.P. , Lichtner M. , D'Agostino C. , Vullo V. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. AIDS 2005; 19: 841–842.

Maggiolo F. , Ripamonti D. , Callegaro A. , Gregis G. , Quinzan G. , Suter F. Quadruple-drug induction HAART in advanced HIV infection. HIV Clin Trials 2005; 6: 1–4.

Mauss S. , Milinkovic A. , Hoffmann C. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. AIDS 2005; 19: 101–102.

Palma P. , Romiti M.L. , Cancrini C. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. AIDS 2007; 21: 2465–2472.

de Truchis P. , Mathez D. , Force G. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial). HIV Clin Trials 2007; 8: 102–104.

Pérez-Elías M.J. , Moreno S. , Gutierrez C. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 2005; 19: 695–698.

Wolbers M. , Opravil M. , von Wyl V. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS 2007; 21: 2201–2207.

Mallolas J. , Pich J. , Penaranda M. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. AIDS 2008; 22: 377–384.

Opravil M. , Hirschel B. , Lazzarin A. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251–1260.

Martínez E. , Arnaiz J.A. , Podzamczer D. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036–1046.

Katlama C. , Fenske S. , Gazzard B. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 79–86.

Maggiolo F. , Ripamonti D. , Ravasio L. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37: 41–49.

Keiser P.H. , Sension M.G. , DeJesus E. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005; 5: 2.

Abgrall S. , Yeni P.G. , Bouchaud O. , Costagliola D. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS 2006; 20: 2099–2106.

Chiesa E. , Bini T. , Adorni F. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther 2003; 8: 27–35.

Clumeck N. , Goebel F. , Rozenbaum W. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517–1526.

Sprenger H.G. , Langebeek N. , Mulder P.G. Abacavir/ lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naive patients: FREE randomized trial interim results. AIDS Patient Care STDS 2010; 24: 361–366.

Pulvirenti J. , Goodwin D. , Slater L. Simplification of protease inhibitor (PI)-containing HAART regimen with abacavir (ABC) maintains viral suppression and favourable adherence in HIV-1 infected adults (COL 30305). 39th Annual Meeting of the Infectious Disease Society of America. 25–28 October 2001, San Francisco, CA, USA. Abstract 689.

Bommenel T. , Launay O. , Meynard J.L. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. J Antimicrob Chemother 2011; 66: 1869–1877.

Markowitz M. , Hill-Zabala C. , Lang J. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/ lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 257–264.

Johnson M. , de Wit S. , Gazzard B. Efficacy and safety of AZT/3TC/ZDV (Trizivir) maintenance treatment after first line quadruple induction therapy- interim 24 weeks: data from AZLF3004/TRISUD. 9th European AIDS Conference. 25–29 October 2003, Warsaw, Poland. Abstract F1/4.

de Wit S. , Johnson M. , Gazzard B. Randomised comparison of maintenance with Trizivir [TZV] + efavirenz [EFV]: TIME study. 7th Interantional Congress on Drug Therapy in HIV Infection. 14–18 November 2004, Glasgow, Scotland. Abstract PL2.4.

Bonjoch A. , Paredes R. , Galvez J. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005; 39: 313–316.

Pulido F. , Perez-Valero I. , Delgado R. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14: 195–201.

Grijsen M.L. , Holman R. , Gras L. No advantage of quadruple- or triple-class antiretroviral therapy as initial treatment in patients with very high viraemia. Antivir Ther 2012; 17: 1609–1613.

Parikh U.M. , Bacheler L. , Koontz D. , Mellors J.W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971–4977.

Martínez E. , Arnaiz J.A. , Podzamczer D. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036–1046.

Sturt A.S. , Dokubo E.K. , Sint T.T. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010; 3: CD008440.

Mallal S.A. , John M. , Moore C.B. , James I.R. , McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309–1316.

Blümer R.M. , van Vonderen M.G. , Sutinen J. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008; 22: 227–236.

van Vonderen M.G. , van Agtmael M.A. , Hassink E.A. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS ONE 2009; 4: e5647.

Gardner K. , Hall P.A. , Chinnery P.F. , Payne B.A. HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies. Toxicol Pathol 2014; 42: 811–822.

Durand M. , Sheehy O. , Baril J.G. , Lelorier J. , Tremblay C.L. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245–253.

Ribaudo H.J. , Benson C.A. , Zheng Y. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52: 929–940.

Bedimo R.J. , Westfall A.O. , Drechsler H. , Vidiella G. , Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53: 84–91.

Sprenger H. , Langebeek N. , Mulder P.G. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral therapy: final 96-week results from the FREE Study. HIV Medicine; in press.